Yan S - Search Results

1

Simpson ML, Desai V, Maro GS, Yan S. Simpson ML, et al. Among authors: yan s. J Manag Care Spec Pharm. 2020 Sep;26(9):1177-1178. doi: 10.18553/jmcp.2020.26.9.1177a. J Manag Care Spec Pharm. 2020. PMID: 32857661 Free PMC article.

2

Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy.

Oldenburg J, Yan S, Maro G, Krishnarajah G, Tiede A. Oldenburg J, et al. Among authors: yan s. Curr Med Res Opin. 2020 Jan;36(1):9-15. doi: 10.1080/03007995.2019.1662675. Epub 2019 Sep 13. Curr Med Res Opin. 2020. PMID: 31469321

3

Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII-SingleChain and other common rFVIII products in Germany.

Olivieri M, Sommerer P, Maro G, Yan S. Olivieri M, et al. Among authors: yan s. Eur J Haematol. 2020 Apr;104(4):310-317. doi: 10.1111/ejh.13378. Epub 2020 Jan 21. Eur J Haematol. 2020. PMID: 31883398 Free PMC article.

4

Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.

Simpson ML, Desai V, Maro GS, Yan S. Simpson ML, et al. Among authors: yan s. J Manag Care Spec Pharm. 2020 Apr;26(4):504-512. doi: 10.18553/jmcp.2020.19318. Epub 2020 Feb 5. J Manag Care Spec Pharm. 2020. PMID: 32020842 Free PMC article.

5

A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.

Yan S, Maro GS, Desai V, Simpson ML. Yan S, et al. J Manag Care Spec Pharm. 2020 Oct;26(10):1258-1265. doi: 10.18553/jmcp.2020.20199. Epub 2020 Aug 21. J Manag Care Spec Pharm. 2020. PMID: 32820685 Free PMC article.

Simpson reports consulting honoraria for participation in advisory boards for Bayer, CSL Behring, HEMA Biologics, Novo Nordisk, Octapharma, and Takeda and speakers bureau for Bayer and Novo Nordisk. Yan and Desai are employees of CSL Behring. Maro is an employee of Adivo A …

Simpson reports consulting honoraria for participation in advisory boards for Bayer, CSL Behring, HEMA Biologics, Novo Nordisk, Octapharma, …

6

Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A.

Olivieri M, Simpson M, Yan S, Fedorovsky J, Zhang X, Tomic R, Pinachyan K, Mancuso ME. Olivieri M, et al. Among authors: yan s. Curr Med Res Opin. 2022 Jul;38(7):1133-1139. doi: 10.1080/03007995.2022.2062180. Epub 2022 May 2. Curr Med Res Opin. 2022. PMID: 35387548

7

Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.

Wilson M, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Yan S. Wilson M, et al. Among authors: yan s. J Manag Care Spec Pharm. 2024 Apr 16:1-12. doi: 10.18553/jmcp.2024.23214. Online ahead of print. J Manag Care Spec Pharm. 2024. PMID: 38625717

8

A systematic review evaluating the efficacy and factor consumption of long-acting recombinant factor VIII products for the prophylactic treatment of hemophilia A.

Graf L, Yan S, Shen MC, Balasa V. Graf L, et al. Among authors: yan s. J Med Econ. 2020 Dec;23(12):1493-1498. doi: 10.1080/13696998.2020.1828092. Epub 2020 Oct 16. J Med Econ. 2020. PMID: 32969738 Free article.

9

Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis.

Yan S, DerSarkissian M, Bhak RH, Lefebvre P, Duh MS, Krishnarajah G. Yan S, et al. Curr Med Res Opin. 2018 Jul;34(7):1261-1269. doi: 10.1080/03007995.2017.1416347. Epub 2018 Jan 10. Curr Med Res Opin. 2018. PMID: 29231748

10

Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.

Davis J, Yan S, Matsushita T, Alberio L, Bassett P, Santagostino E. Davis J, et al. Among authors: yan s. J Med Econ. 2019 Oct;22(10):1014-1021. doi: 10.1080/13696998.2019.1620246. Epub 2019 Jun 5. J Med Econ. 2019. PMID: 31094591 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9,751 results

Search Page